Evaluation and initial management of acute kidney injury

Jonathan Himmelfarb, Michael Joannidis, Bruce Molitoris, Miet Schietz, Mark D. Okusa, David Warnock, Franco Laghi, Stuart L. Goldstein, Richard Prielipp, Chirag R. Parikh, Neesh Pannu, Suzana M. Lobo, Sudhir Shah, Vincent D'Intini, John A. Kellum

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

The evaluation and initial management of patients with acute kidney injury (AKI) should include: (1) an assessment of the contributing causes of the kidney injury, (2) an assessment of the clinical course including comorbidities, (3) a careful assessment of volume status, and (4) the institution of appropriate therapeutic measures designed to reverse or prevent worsening of functional or structural kidney abnormalities. The initial assessment of patients with AKI classically includes the differentiation between prerenal, renal, and postrenal causes. The differentiation between so-called "prerenal" and "renal" causes is more difficult, especially because renal hypoperfusion may coexist with any stage of AKI. Using a modified Delphi approach, the multidisciplinary international working group, generated a set of testable research questions. Key questions included the following: Is there a difference in prognosis between volume-responsive and volume-unresponsive AKI? Are there biomarkers whose patterns (dynamic changes) predict the severity and recovery of AKI (maximal stage of AKI, need for RRT, renal recovery, mortality) and guide therapy? What is the best biomarker to assess prospectively whether AKI is volume responsive? What is the best biomarker to assess the optimal volume status in AKI patients? In evaluating the current literature and ongoing studies, it was though that the answers to the questions posed herein would improve the understanding of AKI, and ultimately patient outcomes.

Original languageEnglish
Pages (from-to)962-967
Number of pages6
JournalClinical Journal of the American Society of Nephrology
Volume3
Issue number4
DOIs
StatePublished - Jul 2008

Fingerprint

Acute Kidney Injury
Kidney
Biomarkers
Comorbidity
Mortality
Wounds and Injuries
Therapeutics
Research

ASJC Scopus subject areas

  • Nephrology
  • Transplantation
  • Epidemiology
  • Critical Care and Intensive Care Medicine

Cite this

Himmelfarb, J., Joannidis, M., Molitoris, B., Schietz, M., Okusa, M. D., Warnock, D., ... Kellum, J. A. (2008). Evaluation and initial management of acute kidney injury. Clinical Journal of the American Society of Nephrology, 3(4), 962-967. https://doi.org/10.2215/CJN.04971107

Evaluation and initial management of acute kidney injury. / Himmelfarb, Jonathan; Joannidis, Michael; Molitoris, Bruce; Schietz, Miet; Okusa, Mark D.; Warnock, David; Laghi, Franco; Goldstein, Stuart L.; Prielipp, Richard; Parikh, Chirag R.; Pannu, Neesh; Lobo, Suzana M.; Shah, Sudhir; D'Intini, Vincent; Kellum, John A.

In: Clinical Journal of the American Society of Nephrology, Vol. 3, No. 4, 07.2008, p. 962-967.

Research output: Contribution to journalArticle

Himmelfarb, J, Joannidis, M, Molitoris, B, Schietz, M, Okusa, MD, Warnock, D, Laghi, F, Goldstein, SL, Prielipp, R, Parikh, CR, Pannu, N, Lobo, SM, Shah, S, D'Intini, V & Kellum, JA 2008, 'Evaluation and initial management of acute kidney injury', Clinical Journal of the American Society of Nephrology, vol. 3, no. 4, pp. 962-967. https://doi.org/10.2215/CJN.04971107
Himmelfarb, Jonathan ; Joannidis, Michael ; Molitoris, Bruce ; Schietz, Miet ; Okusa, Mark D. ; Warnock, David ; Laghi, Franco ; Goldstein, Stuart L. ; Prielipp, Richard ; Parikh, Chirag R. ; Pannu, Neesh ; Lobo, Suzana M. ; Shah, Sudhir ; D'Intini, Vincent ; Kellum, John A. / Evaluation and initial management of acute kidney injury. In: Clinical Journal of the American Society of Nephrology. 2008 ; Vol. 3, No. 4. pp. 962-967.
@article{7d6d92b0275c4fbc8560527d8e9c69c2,
title = "Evaluation and initial management of acute kidney injury",
abstract = "The evaluation and initial management of patients with acute kidney injury (AKI) should include: (1) an assessment of the contributing causes of the kidney injury, (2) an assessment of the clinical course including comorbidities, (3) a careful assessment of volume status, and (4) the institution of appropriate therapeutic measures designed to reverse or prevent worsening of functional or structural kidney abnormalities. The initial assessment of patients with AKI classically includes the differentiation between prerenal, renal, and postrenal causes. The differentiation between so-called {"}prerenal{"} and {"}renal{"} causes is more difficult, especially because renal hypoperfusion may coexist with any stage of AKI. Using a modified Delphi approach, the multidisciplinary international working group, generated a set of testable research questions. Key questions included the following: Is there a difference in prognosis between volume-responsive and volume-unresponsive AKI? Are there biomarkers whose patterns (dynamic changes) predict the severity and recovery of AKI (maximal stage of AKI, need for RRT, renal recovery, mortality) and guide therapy? What is the best biomarker to assess prospectively whether AKI is volume responsive? What is the best biomarker to assess the optimal volume status in AKI patients? In evaluating the current literature and ongoing studies, it was though that the answers to the questions posed herein would improve the understanding of AKI, and ultimately patient outcomes.",
author = "Jonathan Himmelfarb and Michael Joannidis and Bruce Molitoris and Miet Schietz and Okusa, {Mark D.} and David Warnock and Franco Laghi and Goldstein, {Stuart L.} and Richard Prielipp and Parikh, {Chirag R.} and Neesh Pannu and Lobo, {Suzana M.} and Sudhir Shah and Vincent D'Intini and Kellum, {John A.}",
year = "2008",
month = "7",
doi = "10.2215/CJN.04971107",
language = "English",
volume = "3",
pages = "962--967",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "4",

}

TY - JOUR

T1 - Evaluation and initial management of acute kidney injury

AU - Himmelfarb, Jonathan

AU - Joannidis, Michael

AU - Molitoris, Bruce

AU - Schietz, Miet

AU - Okusa, Mark D.

AU - Warnock, David

AU - Laghi, Franco

AU - Goldstein, Stuart L.

AU - Prielipp, Richard

AU - Parikh, Chirag R.

AU - Pannu, Neesh

AU - Lobo, Suzana M.

AU - Shah, Sudhir

AU - D'Intini, Vincent

AU - Kellum, John A.

PY - 2008/7

Y1 - 2008/7

N2 - The evaluation and initial management of patients with acute kidney injury (AKI) should include: (1) an assessment of the contributing causes of the kidney injury, (2) an assessment of the clinical course including comorbidities, (3) a careful assessment of volume status, and (4) the institution of appropriate therapeutic measures designed to reverse or prevent worsening of functional or structural kidney abnormalities. The initial assessment of patients with AKI classically includes the differentiation between prerenal, renal, and postrenal causes. The differentiation between so-called "prerenal" and "renal" causes is more difficult, especially because renal hypoperfusion may coexist with any stage of AKI. Using a modified Delphi approach, the multidisciplinary international working group, generated a set of testable research questions. Key questions included the following: Is there a difference in prognosis between volume-responsive and volume-unresponsive AKI? Are there biomarkers whose patterns (dynamic changes) predict the severity and recovery of AKI (maximal stage of AKI, need for RRT, renal recovery, mortality) and guide therapy? What is the best biomarker to assess prospectively whether AKI is volume responsive? What is the best biomarker to assess the optimal volume status in AKI patients? In evaluating the current literature and ongoing studies, it was though that the answers to the questions posed herein would improve the understanding of AKI, and ultimately patient outcomes.

AB - The evaluation and initial management of patients with acute kidney injury (AKI) should include: (1) an assessment of the contributing causes of the kidney injury, (2) an assessment of the clinical course including comorbidities, (3) a careful assessment of volume status, and (4) the institution of appropriate therapeutic measures designed to reverse or prevent worsening of functional or structural kidney abnormalities. The initial assessment of patients with AKI classically includes the differentiation between prerenal, renal, and postrenal causes. The differentiation between so-called "prerenal" and "renal" causes is more difficult, especially because renal hypoperfusion may coexist with any stage of AKI. Using a modified Delphi approach, the multidisciplinary international working group, generated a set of testable research questions. Key questions included the following: Is there a difference in prognosis between volume-responsive and volume-unresponsive AKI? Are there biomarkers whose patterns (dynamic changes) predict the severity and recovery of AKI (maximal stage of AKI, need for RRT, renal recovery, mortality) and guide therapy? What is the best biomarker to assess prospectively whether AKI is volume responsive? What is the best biomarker to assess the optimal volume status in AKI patients? In evaluating the current literature and ongoing studies, it was though that the answers to the questions posed herein would improve the understanding of AKI, and ultimately patient outcomes.

UR - http://www.scopus.com/inward/record.url?scp=49149104181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49149104181&partnerID=8YFLogxK

U2 - 10.2215/CJN.04971107

DO - 10.2215/CJN.04971107

M3 - Article

VL - 3

SP - 962

EP - 967

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 4

ER -